NCT06363487 (OxSENSE) is a NA clinical trial of Semaglutide, 0.5 mg/mL in Cognitive Change, sponsored by University of Oxford.

Who is sponsoring NCT06363487?

NCT06363487 is sponsored by University of Oxford.

What drugs are being tested in NCT06363487?

Interventions in NCT06363487: Semaglutide, 0.5 mg/mL, Placebo, 0.9% NaCl 1.5mL.

What condition does NCT06363487 study?

NCT06363487 studies Cognitive Change.

Is NCT06363487 still recruiting?

NCT06363487 is currently completed. Last updated 6 June 2025.

Last reviewed 2025-06-06 · How we verify

NCT06363487: OxSENSE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Semaglutide and Cognition in Healthy Volunteers

Completed NA Last updated 6 June 2025

What this trial tests

NA trial testing Semaglutide, 0.5 mg/mL in Cognitive Change in 70 participants. Completed in 11 December 2024.

Timeline

6 June 2024

Primary endpoint
11 December 2024

11 December 2024

Quick facts

Lead sponsor	University of Oxford
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	basic science
Enrollment	70
Start date	6 June 2024
Primary completion	11 December 2024
Estimated completion	11 December 2024
Sites	1 location across United Kingdom

Drugs / interventions tested

Semaglutide, 0.5 mg/mL — full drug profile →
Placebo, 0.9% NaCl 1.5mL

Conditions studied

Cognitive Change — all drugs for Cognitive Change →

Sponsor

University of Oxford

Who can join

Adults 21 to 55, any sex, with Cognitive Change. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA). It is a safe medication approved for use in type-2 diabetes mellitus (T2DM) and obesity. Primarily, it works by counteracting insulin-resistance and inducing weight loss. It also acts on several other interconnected neurobiological, immunological (esp. inflammatory), endocrine-metabolic, and gut-brain axis processes that play a role in depressive symptoms. Its effects on cognition and energy are currently unknown. In this study we are using semaglutide as an experimental tool to further investigate these relationships.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis.
Seminer A, Mulihano A, O'Brien C, Krewer F, et al · · 2025 · cited 48× · PMID 40193122 · DOI 10.1001/jamaneurol.2025.0360
Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease and Parkinson's disease.
Hong CT, Chen JH, Hu CJ. · · 2024 · cited 35× · PMID 39501255 · DOI 10.1186/s12929-024-01090-x
Glucagon-like peptide-1 medicines in neurological and psychiatric disorders.
Fang S, Cui F, Drucker DJ. · · 2025 · PMID 41406951 · DOI 10.1016/j.xcrm.2025.102511

Verify or expand the search:

Other trials of Semaglutide, 0.5 mg/mL

Trials testing the same drug.

NCT03598621 — A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools · Phase 1 · completed

Other recruiting trials for Cognitive Change

Currently open trials in the same condition.

NCT07147894 — Executive Function Training for Children and Adolescents · NA · recruiting
NCT07383324 — Heat Stress in Individuals With Schizophrenia · NA · recruiting
NCT07261202 — Impact of Indoor Overheating on Physiological Strain in Children · NA · recruiting
NCT07267598 — Suitability of a 26 °C Indoor Environment for Mitigating Heat Strain in Young Adults · NA · recruiting
NCT07054723 — Surviving Daily Life · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06363487 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 6 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06363487.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing